NRG Oncology Assessment of Artificial Intelligence Deep Learning-Based Auto-segmentation for Radiation Therapy: Current Developments, Clinical Considerations, and Future Directions.

Journal: International journal of radiation oncology, biology, physics
Published Date:

Abstract

Deep learning neural networks (DLNN) in Artificial intelligence (AI) have been extensively explored for automatic segmentation in radiotherapy (RT). In contrast to traditional model-based methods, data-driven AI-based models for auto-segmentation have shown high accuracy in early studies in research settings and controlled environment (single institution). Vendor-provided commercial AI models are made available as part of the integrated treatment planning system (TPS) or as a stand-alone tool that provides streamlined workflow interacting with the main TPS. These commercial tools have drawn clinics' attention thanks to their significant benefit in reducing the workload from manual contouring and shortening the duration of treatment planning. However, challenges occur when applying these commercial AI-based segmentation models to diverse clinical scenarios, particularly in uncontrolled environments. Contouring nomenclature and guideline standardization has been the main task undertaken by the NRG Oncology. AI auto-segmentation holds the potential clinical trial participants to reduce interobserver variations, nomenclature non-compliance, and contouring guideline deviations. Meanwhile, trial reviewers could use AI tools to verify contour accuracy and compliance of those submitted datasets. In recognizing the growing clinical utilization and potential of these commercial AI auto-segmentation tools, NRG Oncology has formed a working group to evaluate the clinical utilization and potential of commercial AI auto-segmentation tools. The group will assess in-house and commercially available AI models, evaluation metrics, clinical challenges, and limitations, as well as future developments in addressing these challenges. General recommendations are made in terms of the implementation of these commercial AI models, as well as precautions in recognizing the challenges and limitations.

Authors

  • Yi Rong
    Department of Radiation Oncology, University of California Davis Medical Center, Sacramento, CA, United States.
  • Quan Chen
    Management School, Zhongshan Institute, University of Electronic Science and Technology of China, Guangdong, 528402, China.
  • Yabo Fu
    Department of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA.
  • Xiaofeng Yang
    Department of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA.
  • Hania A Al-Hallaq
    Department of Radiation Oncology, University of Chicago Comprehensive Cancer Center, Chicago, Illinois.
  • Q Jackie Wu
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC, United States.
  • Lulin Yuan
    Department of Radiation Oncology, Virginia Commonwealth University, Richmond, Virginia. Electronic address: Lulin.yuan@vcuhealth.org.
  • Ying Xiao
    Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA.
  • Bin Cai
    Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Kujtim Latifi
    Radiation Oncology, Moffitt Cancer Center, Tampa, Florida, USA.
  • Stanley H Benedict
    Department of Radiation Oncology, University of California Davis Medical Center, Sacramento, CA, United States.
  • Jeffrey C Buchsbaum
    Radiation Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • X Sharon Qi